Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal Cancer

NCT05725200 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT05725200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05725200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal Cancer
Lead sponsor
Oslo University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 27, 2022
Completion date
December 31, 2040
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer